These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 20629603

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Influence of ABCB1 polymorphisms and haplotypes on tacrolimus nephrotoxicity and dosage requirements in children with liver transplant.
    Hawwa AF, McKiernan PJ, Shields M, Millership JS, Collier PS, McElnay JC.
    Br J Clin Pharmacol; 2009 Sep; 68(3):413-21. PubMed ID: 19740399
    [Abstract] [Full Text] [Related]

  • 3. Expression of CYP3A5 and P-glycoprotein in renal allografts with histological signs of calcineurin inhibitor nephrotoxicity.
    Metalidis C, Lerut E, Naesens M, Kuypers DR.
    Transplantation; 2011 May 27; 91(10):1098-102. PubMed ID: 21544031
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients.
    Quteineh L, Verstuyft C, Furlan V, Durrbach A, Letierce A, Ferlicot S, Taburet AM, Charpentier B, Becquemont L.
    Basic Clin Pharmacol Toxicol; 2008 Dec 27; 103(6):546-52. PubMed ID: 19067682
    [Abstract] [Full Text] [Related]

  • 6. Severe acute nephrotoxicity in a kidney transplant patient despite low tacrolimus levels: a possible interaction between donor and recipient genetic polymorphisms.
    Quaglia M, Terrazzino S, Boldorini R, Stratta P, Genazzani AA.
    J Clin Pharm Ther; 2013 Aug 27; 38(4):333-6. PubMed ID: 23574377
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. CYP3A5 *1 allele: impacts on early acute rejection and graft function in tacrolimus-based renal transplant recipients.
    Min SI, Kim SY, Ahn SH, Min SK, Kim SH, Kim YS, Moon KC, Oh JM, Kim SJ, Ha J.
    Transplantation; 2010 Dec 27; 90(12):1394-400. PubMed ID: 21076384
    [Abstract] [Full Text] [Related]

  • 9. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation.
    Hauser IA, Schaeffeler E, Gauer S, Scheuermann EH, Wegner B, Gossmann J, Ackermann H, Seidl C, Hocher B, Zanger UM, Geiger H, Eichelbaum M, Schwab M.
    J Am Soc Nephrol; 2005 May 27; 16(5):1501-11. PubMed ID: 15772250
    [Abstract] [Full Text] [Related]

  • 10. The pharmacogenetics of calcineurin inhibitor-related nephrotoxicity.
    Hesselink DA, Bouamar R, van Gelder T.
    Ther Drug Monit; 2010 Aug 27; 32(4):387-93. PubMed ID: 20571464
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Individualized dosage regimen of immunosuppressive drugs based on pharmacokinetic and pharmacodynamic analysis].
    Fukudo M.
    Yakugaku Zasshi; 2007 Jul 27; 127(7):1081-9. PubMed ID: 17603267
    [Abstract] [Full Text] [Related]

  • 13. Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism.
    Zheng H, Zeevi A, Schuetz E, Lamba J, McCurry K, Griffith BP, Webber S, Ristich J, Dauber J, Iacono A, Grgurich W, Zaldonis D, McDade K, Zhang J, Burckart GJ.
    J Clin Pharmacol; 2004 Feb 27; 44(2):135-40. PubMed ID: 14747421
    [Abstract] [Full Text] [Related]

  • 14. Genetic polymorphisms and individualized tacrolimus dosing.
    López-Montenegro Soria MA, Kanter Berga J, Beltrán Catalán S, Milara Payá J, Pallardó Mateu LM, Jiménez Torres NV.
    Transplant Proc; 2010 Oct 27; 42(8):3031-3. PubMed ID: 20970601
    [Abstract] [Full Text] [Related]

  • 15. Biotransformation enzymes and drug transporters pharmacogenetics in relation to immunosuppressive drugs: impact on pharmacokinetics and clinical outcome.
    Mourad M, Wallemacq P, De Meyer M, Malaise J, De Pauw L, Eddour DC, Goffin E, Lerut J, Haufroid V.
    Transplantation; 2008 Apr 15; 85(7 Suppl):S19-24. PubMed ID: 18401258
    [Abstract] [Full Text] [Related]

  • 16. Genetic factors for individual administration of immunosuppressants in organ transplantation.
    Yu SF, Wu LH, Zheng SS.
    Hepatobiliary Pancreat Dis Int; 2006 Aug 15; 5(3):337-44. PubMed ID: 16911928
    [Abstract] [Full Text] [Related]

  • 17. The effect of MDR1 (ABCB1) polymorphism on the pharmacokinetic of tacrolimus in Turkish renal transplant recipients.
    Akbas SH, Bilgen T, Keser I, Tuncer M, Yucetin L, Tosun O, Gultekin M, Luleci G.
    Transplant Proc; 2006 Jun 15; 38(5):1290-2. PubMed ID: 16797284
    [Abstract] [Full Text] [Related]

  • 18. Tacrolimus dosing in Chinese renal transplant patients is related to MDR1 gene C3435T polymorphisms.
    Li D, Gui R, Li J, Huang Z, Nie X.
    Transplant Proc; 2006 Nov 15; 38(9):2850-2. PubMed ID: 17112846
    [Abstract] [Full Text] [Related]

  • 19. Clinical pharmacogenetics of immunosuppressive drugs in organ transplantation.
    Szekeres T, Haushofer A.
    Pharmacogenomics; 2005 Mar 15; 6(2):163-8. PubMed ID: 15882134
    [Abstract] [Full Text] [Related]

  • 20. Relationship between postoperative erythromycin breath test and early morbidity in liver transplant recipients.
    Schmidt LE, Rasmussen A, Kirkegaard P, Dalhoff K.
    Transplantation; 2003 Jul 27; 76(2):358-63. PubMed ID: 12883193
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.